Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1002/pst.1742 http://scihub22266oqcxt.onion/10.1002/pst.1742 C5405342!5405342!26932771     free     free     free       Pharm+Stat 2016 ; 15 (4): 333-40 Nephropedia Template TP {{tp|p=26932771|t=2016. An optimal stratified Simon two?stage design |pdf=|usr=}}{{26932771}} gab.com Text An optimal stratified Simon two stage design JO: Pharm Stat http://www.kidney.de/pget.php?&tw=1&pmid=26932771 #FOAvip In Phase II oncology trials, therapies are increasingly being evaluated for their effectiveness in specific populations of interest. Such targeted trials require designs that allow for stratification based on the participants' molecular characterisation. A targeted design proposed by Jones and Holmgren (JH) Jones CL, Holmgren E: ?An adaptive Simon two?stage design for phase 2 studies of targeted therapies?, Contemporary Clinical Trials 28 (2007) 654?661.determines whether a drug only has activity in a disease sub?population or in the wider disease population. Their adaptive design uses results from a single interim analysis to decide whether to enrich the study population with a subgroup or not; it is based on two parallel Simon two?stage designs. We study the JH design in detail and extend it by providing a few alternative ways to control the familywise error rate, in the weak sense as well as the strong sense. We also introduce a novel optimal design by minimising the expected sample size. Our extended design contributes to the much needed framework for conducting Phase II trials in stratified medicine. © 2016 The Authors Pharmaceutical Statistics Published by John Wiley & Sons Ltd Twit Text FOAVip An optimal stratified Simon two stage design ????Pharm Stat http://www.kidney.de/pget.php?&tw=1&pmid=26932771 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=26932771 #FOAvip English Wikipedia <ref>{{Cite pmid|26932771}}</ref> An optimal stratified Simon two?stage design #MMPMID26932771 Parashar D; Bowden J; Starr C; Wernisch L; Mander A Pharm Stat 2016[Jul]; 15 (4): 333-40 PMID26932771show ga In Phase II oncology trials, therapies are increasingly being evaluated for their effectiveness in specific populations of interest. Such targeted trials require designs that allow for stratification based on the participants' molecular characterisation. A targeted design proposed by Jones and Holmgren (JH) Jones CL, Holmgren E: ?An adaptive Simon two?stage design for phase 2 studies of targeted therapies?, Contemporary Clinical Trials 28 (2007) 654?661.determines whether a drug only has activity in a disease sub?population or in the wider disease population. Their adaptive design uses results from a single interim analysis to decide whether to enrich the study population with a subgroup or not; it is based on two parallel Simon two?stage designs. We study the JH design in detail and extend it by providing a few alternative ways to control the familywise error rate, in the weak sense as well as the strong sense. We also introduce a novel optimal design by minimising the expected sample size. Our extended design contributes to the much needed framework for conducting Phase II trials in stratified medicine. © 2016 The Authors Pharmaceutical Statistics Published by John Wiley & Sons Ltd äAn optimal stratified Simon two?stage design (epmc).pdf DeepDyve Pubget Overpricing